The U.S. Food and Drug Administration (FDA) published a paper March 15, to update the public about intra-agency activities to oversee artificial intelligence (AI)-enabled healthcare technologies. The paper summarizes priorities shared across the biologics, drugs and medical devices domains of FDA jurisdiction.
Four general focus areas are discussed: fostering collaboration with stakeholders; developing appropriate regulatory approaches; promoting development of standards and best practices; and supporting research on performance evaluation. Moving forward, the FDA intends to evolve its own regulatory approaches with the continued progression of AI tools.
For more information about various American College of Radiology®(ACR®) AI-specific initiatives, visit the ACR Data Science Institute®. For more information about FDA oversight and digital health policy, contact Michael Peters, ACR Senior Government Affairs Director.
Make America Healthy Again
President Trump released an Executive Order (EO) establishing the "Make America Healthy Again (MAHA) Commission,” Feb. 13 to be led by the new Department of Health and Human Services Secretary Robert F. Kennedy Jr.
Read moreScope of Practice Bills Introduced At State Legislative Level
The American College of Radiology® (ACR®) is tracking more than 58 scope of practice bills across 22 states with more expected to be considered.
Read moreACR Others Challenge MAC Position on Minimally Invasive Arthrodesis of the Sacroiliac Joint
The American College of Radiology® (ACR®) and other medical specialty societies that use or perform interventional pain and spine procedures told three of the seven Medicare Administrative Contractors (MACs) that implementation of a new policy as written could limit access to a safe, effective and durable treatment option, potentially exacerbating healthcare disparities among Medicare patients.
Read more